ZBTB7A, a miR-144-3p targeted gene, accelerates bladder cancer progression via downregulating HIC1 expression.
Bladder cancer
HIC1
ZBTB7A
miR-144-3p
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
02 May 2022
02 May 2022
Historique:
received:
19
11
2021
accepted:
18
04
2022
entrez:
3
5
2022
pubmed:
4
5
2022
medline:
4
5
2022
Statut:
epublish
Résumé
Zinc finger and BTB domain-containing 7A (ZBTB7A) is a member of the POK family of transcription factors that plays an oncogenic or tumor-suppressive role in different cancers depending on the type and genetic context of cancer. However, the function and molecular mechanism of ZBTB7A in bladder cancer (BC) remain elusive. The role of ZBTB7A in bladder cancer was detected by colony formation, transwell, and tumor formation assays. The expression levels of ZBTB7A, HIC1, and miR-144-3p were analyzed by qRT-PCR and Western blot. Bioinformatics analysis and a dual-luciferase reporter assay were used to assess the effect of ZBTB7A on the promoter activity of HIC1. The present study revealed that knockdown of ZBTB7A suppressed BC cell growth and migration, as indicated by an approximately 50% reduction in the number of colonies and an approximately 70% reduction in the number of migrated cells. Loss of ZBTB7A inhibited tumor growth in vivo, resulting in a 75% decrease in tumor volume and an 80% decrease in tumor weight. Further mechanistic studies revealed that ZBTB7A bound to the hypermethylated in cancer 1 (HIC1) promoter and downregulated HIC1 expression, accelerating the malignant behavior of BC. Increased expression of ZBTB7A in BC tissues was negatively corrected with the expression of HIC1. Moreover, ZBTB7A was a target of miR-144-3p, which decreased ZBTB7A expression in BC. Our data demonstrate that ZBTB7A, a targeted gene of miR-144-3p, promoted tumorigenesis of BC through downregulating HIC1 expression.
Sections du résumé
BACKGROUND
BACKGROUND
Zinc finger and BTB domain-containing 7A (ZBTB7A) is a member of the POK family of transcription factors that plays an oncogenic or tumor-suppressive role in different cancers depending on the type and genetic context of cancer. However, the function and molecular mechanism of ZBTB7A in bladder cancer (BC) remain elusive.
METHODS
METHODS
The role of ZBTB7A in bladder cancer was detected by colony formation, transwell, and tumor formation assays. The expression levels of ZBTB7A, HIC1, and miR-144-3p were analyzed by qRT-PCR and Western blot. Bioinformatics analysis and a dual-luciferase reporter assay were used to assess the effect of ZBTB7A on the promoter activity of HIC1.
RESULTS
RESULTS
The present study revealed that knockdown of ZBTB7A suppressed BC cell growth and migration, as indicated by an approximately 50% reduction in the number of colonies and an approximately 70% reduction in the number of migrated cells. Loss of ZBTB7A inhibited tumor growth in vivo, resulting in a 75% decrease in tumor volume and an 80% decrease in tumor weight. Further mechanistic studies revealed that ZBTB7A bound to the hypermethylated in cancer 1 (HIC1) promoter and downregulated HIC1 expression, accelerating the malignant behavior of BC. Increased expression of ZBTB7A in BC tissues was negatively corrected with the expression of HIC1. Moreover, ZBTB7A was a target of miR-144-3p, which decreased ZBTB7A expression in BC.
CONCLUSION
CONCLUSIONS
Our data demonstrate that ZBTB7A, a targeted gene of miR-144-3p, promoted tumorigenesis of BC through downregulating HIC1 expression.
Identifiants
pubmed: 35501800
doi: 10.1186/s12935-022-02596-w
pii: 10.1186/s12935-022-02596-w
pmc: PMC9063087
doi:
Types de publication
Journal Article
Langues
eng
Pagination
179Subventions
Organisme : National Natural Science Foundation of China
ID : 11872146
Informations de copyright
© 2022. The Author(s).
Références
Cancer Lett. 2019 Apr 28;448:105-116
pubmed: 30753838
Cancer Lett. 2020 Jul 28;483:22-34
pubmed: 32348807
Nat Genet. 2013 Jul;45(7):739-746
pubmed: 23727861
Aging (Albany NY). 2021 Jul 5;13(13):17349-17369
pubmed: 34226299
Int J Mol Sci. 2011;12(9):5672-83
pubmed: 22016618
Tumour Biol. 2015 Feb;36(2):1155-62
pubmed: 25722217
Oncogene. 2017 Jan 5;36(1):35-46
pubmed: 27270441
Exp Hematol. 2020 Jul;87:20-24.e1
pubmed: 32525064
Hum Genomics. 2019 Dec 10;13(1):66
pubmed: 31823818
Int J Biochem Cell Biol. 2009 Jan;41(1):26-33
pubmed: 18723112
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Invest. 2018 Dec 3;128(12):5235-5250
pubmed: 30204129
Int J Oncol. 2018 Nov;53(5):2102-2110
pubmed: 30106136
Nature. 2005 Jan 20;433(7023):278-85
pubmed: 15662416
J Biochem. 2019 Dec 1;166(6):485-493
pubmed: 31385585
Biochem Biophys Res Commun. 2017 Apr 22;486(1):49-56
pubmed: 28242196
Cell Death Dis. 2020 Oct 13;11(10):851
pubmed: 33051436
Mol Cancer Res. 2015 Aug;13(8):1206-17
pubmed: 25995384
Cell Death Differ. 2020 Jun;27(6):1747-1764
pubmed: 31748695
BMC Gastroenterol. 2020 Nov 9;20(1):370
pubmed: 33167891
Mol Biol Rep. 2021 May;48(5):4703-4719
pubmed: 34014468
J Cell Mol Med. 2021 Feb;25(4):1867-1883
pubmed: 33417281
Cancer Lett. 2015 Dec 28;369(2):376-85
pubmed: 26404754
Mol Carcinog. 2016 Dec;55(12):2001-2009
pubmed: 26713860
Acta Biochim Biophys Sin (Shanghai). 2021 Oct 12;53(10):1398-1407
pubmed: 34435195
Cancer Res. 2019 Oct 15;79(20):5260-5271
pubmed: 31444154
J Cell Biochem. 2019 Apr;120(4):6471-6481
pubmed: 30417565
Dev Cell. 2009 Oct;17(4):527-40
pubmed: 19853566
Br J Cancer. 2015 Jul 14;113(2):282-9
pubmed: 26057453
Biochem Biophys Res Commun. 2014 Jan 24;443(4):1226-31
pubmed: 24393848
Front Oncol. 2020 Jan 31;10:47
pubmed: 32083004
Nature. 2017 Nov 8;551(7679):S33
pubmed: 29117156
Neoplasia. 2017 Nov;19(11):908-918
pubmed: 28942243
EXCLI J. 2020 Apr 07;19:476-489
pubmed: 32398971
Neurosurg Focus. 2005 Oct 15;19(4):E8
pubmed: 16241110
Nat Rev Cancer. 2021 Feb;21(2):104-121
pubmed: 33268841
J Transl Med. 2021 Oct 17;19(1):432
pubmed: 34657624
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
Cell Death Dis. 2021 May 2;12(5):438
pubmed: 33935281